Fellowships Awarded

Many strong applications were received this year for both the C-SPIN/Bayer Fellowship and the C-SPIN Fellowship. We had 7 applicants in total for the 2016 awards.

We congratulate the following:


Dr. William McIntyre  – William was born in Fredericton, New Brunswick and received his Bachelor of Science degree from Mount Allison University.  He attended Queen’s University for Medical School and Internal Medicine Residency.  He is currently in his final year of training in the Adult Cardiology residency program at the University of Manitoba, where he serves as the Chief Resident. In July 2016, he will begin a clinical and research fellowship in heart rhythm at McMaster University.  William is a member of the executive of the Canadian Cardiovascular Society’s Trainee Committee, the Cardiac Arrhythmia Network of Canada’s Trainee Committee and the Board of Directors of the Canadian Heart Rhythm Society.  William’s research interests include atrial fibrillation and cardiac devices. The focus of his research fellowship will be investigating patients with atrial fibrillation that occurs transiently with stress (AFOTS) and evaluating their risk of recurrent atrial fibrillation and stroke.  Upon completion of his training, Dr. McIntyre aims to obtain an appointment in clinical and academic cardiology at a Canadian University.


Awardees of the C-SPIN Bayer Junior Faculty Award & Fellowship:


Dr. Jason Roberts from Western University. Received this award based on GENE-AF trial: through partnerships with three large multi-centred Canadian clinical trials examining the role of catheter ablation as a treatment for atrial fibrillation (AF), and two high volume Canadian AF ablation centers, the GENEtic Predictors of Successful Atrial Fibrillation Therapy (GENE-AF) study proposes to identify GENETIC VARIANTS that impact clinical efficacy.  Jason assumed the role of Clinical Cardiac Electrophysiologist and Assistant Professor of Medicine at Western University in London, Ontario, Canada in August, 2015.  He completed his training in cardiac electrophysiology at the University of California, San Francisco (UCSF) during a 3 year fellowship that also included a year of dedicated research.  During this period, he also obtained a Master’s Degree in Epidemiology and Biostatistics from UCSF.  He completed his Cardiology Fellowship at the University of Ottawa Heart Institute, his Internal Medicine Residency at the University of Toronto, and Medical School at Memorial University.  As a clinician scientist, his research centers on the genetics of cardiac arrhythmias.  During his training in Ottawa, he worked in the laboratory of Dr. Michael Gollob and studied the genetics of atrial fibrillation and inherited arrhythmia syndromes, including the short QT syndrome.  He also worked with Dr. Derek So and Spartan Bioscience to develop a point-of-care genetic test for clopidogrel, the results of the clinical trial being subsequently published in the Lancet.   In London, his research program is focused on all aspects of arrhythmia genetics with a particular emphasis on gene discovery and pharmacogenomic applications.


Dr. Thalia Field from the University of British Columbia, is receiving this award for the HI-ROLLER (HIgh-Risk patient protocOL for LEft atRial appendage closure) study, a pilot study of high-risk patients for intracranial hemorrhage undergoing left atrial appendage closure who will recieve 1 month of dual antiplatelet therapy and subsequent ASA monotherapy.  This unblinded proof-of-concept study will ascertain: (1) Feasibility of recruitment for a larger trial for ICH/at-risk patients, (2) Phenotype of ICH (amyloid angiopathy-probable versus hypertensive-probable), and types of at-risk patients at risk for first ICH (high risk amyloid angiopathy-probable neuroimaging as given by high number of microbleeds or presence of cortical superficial siderosis), (3) Safety of LAAC with 1 month dual antiplatelet therapy and subsequent ASA monotherapy in patients with ICH/at-risk as determined using clinical and MRI surrogate markers. Thalia Field’s interest in stroke began with her work as a summer student with the Calgary Stroke Program in 2001.  She went on to complete her MD at Dalhousie University, followed by a neurology residency at the University of British Columbia and stroke fellowship training at the University of British Columbia and the University of Calgary.  She is an Assistant Professor with the Faculty of Medicine at the University of British Columbia and a stroke neurologist and fellowship program director for the Vancouver Stroke Program.  Her primary research interest is diagnosis and therapy of small vessel disease.

Congratulations again to all the awardees from whom we expect to hear great things in their research careers.